Ayahuasca for Suicidality

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published: February 18, 2026
Journal: JAMA Psychiatry
Authors: Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published: August 1, 2025
Journal: Preventative Medicine Reports
Authors: Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.

Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published: April 22, 2025
Journal: Neuropsychopharmacology
Authors: Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Costa-Macedo, J. V., da Cruz Nunes, J. A., Araújo, D. B., de Araujo Costa Neto, L. A., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Arcoverde, E., Galvão-Coelho, N. L.

Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published: March 10, 2023
Journal: Psyarxiv
Authors: Turkia, M.

Paywallindividual

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

This analysis of an earlier open-label study (n=15) on Ayahuasca, found significant (Hedges' g = 1.75) and sustained decreases in suicidality in people with depression (MDD).

Published: October 29, 2020
Journal: Psychopharmacology
Authors: Zeifman, R. J., Dos Santos, R. G., Sanches, R. F., de Lima Osório, F., Hallak, J. E., Weissman, C. R.

Open Accessindividual

The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial.

This secondary analysis of a double-blind, parallel-arm, randomised placebo-controlled trial (n=29) investigates the impact of ayahuasca on suicidality (SI) in individuals with treatment-resistant depression (TRD). It found that ayahuasca may show potential as a fast-acting and innovative intervention for SI, but didn't find significant results (only a trend with a large effect size). This is the first study to investigate the use of ayahuasca for SI.

Published: November 19, 2019
Journal: Frontiers in Pharmacology
Authors: Araújo, D. B., Zeifman, R. J., Palhano-Fontes, F., Hallak, J. E., Arcoverde, E., Maia-de-Oliveira, J. P.

Company

Product

Legal

Ayahuasca

Suicidality

Academic Research

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

Health-related behavioral changes following the use of psychedelics in naturalistic settings

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial

The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial.

Clinical Trials

Explore further